As we near the end of the year, we'd like to thank our team, partners, investigators, the patient community, and all who continue to support our efforts to develop potentially transformative therapies for the retinal community. Wishing you happy holidays ahead!

We’re excited to welcome Federico Grossi, M.D., Ph.D. as our new chief medical officer. He brings a wealth of experience in clinical and regulatory strategy and will support the clinical development of our lead candidate UBX1325. $UBX ir.unitybiotechnology.com/news-releases/…

We’re headed to #JPM25! Just a short drive from our South San Francisco office, we’re looking forward to gathering with new and familiar faces onsite. On the ground and interested in connecting? Reach out here: bit.ly/3ZXlVgJ

We’re buzzing with energy from #JPM25 — it’s always a pleasure to connect with investors and potential partners in #biotech. We're looking forward to sharing topline results from the Ph2B ASPIRE study in Q1 as we continue efforts to bring forward new treatment options for #DME.

Ever wonder what our executives’ lives are like outside of advancing our #DME senolytic candidate? Our CMO Federico Grossi, M.D., Ph.D. shared how he unwinds in his garage-turned-workshop in this week’s edition of STAT' “Up and down the ladder” below. statnews.com/pharmalot/2025…

Where can #DME patients turn to after anti-VEGF treatment plateaus? #UBX1325’s novel MOA shows promise for additional visual gains, even after anti-VEGF therapy. Hear from Dr. Dante Pieramici on how UNITY’s senolytic approach could redefine DME care. bit.ly/3XpnuCP

UNITY is at the forefront of developing the first ever senolytic candidate that aims to restore diseased tissues to a healthier state. See how #UBX1325 targets senescent cells in the diabetic retina, clearing inflammation and potentially restoring vision in #DME patients.

To our dedicated staff—you are the heart of our company. At UNITY, we foster an inclusive culture that celebrates individuality and embraces our rich diversity. We’re grateful to our wonderful team for continuously embodying the heart of UNITY! #EmployeeAppreciation

#UBX1325 aims to eliminate the senescent cells and therefore a source of inflammation and anti-VEGF production. Stay tuned as we share topline results from our Ph2b ASPIRE study evaluating UBX1325 in #DME patients who are not achieving optimal benefit from anti-VEGF drugs.

The growing #DME population faces significant challenges, with many experiencing suboptimal treatment response and vision decline. #UBX1325 aims to address this unmet need and improve long-term outcomes. Learn more below and stay tuned for Phase 2b ASPIRE study results.

Today we announced our Q4 and full year 2024 financial results and business updates, including progress on our senolytic pipeline and the upcoming 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (#DME). See the full release: ir.unitybiotechnology.com/news-releases/…

Today, we welcomed Yehia Hashad, MD, to our board of directors. As an experienced ophthalmologist and pharmaceutical executive, he will help guide the continued execution of our strategic vision of UBX1325 in #DME ir.unitybiotechnology.com/news-releases/…

Today we announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (#DME) who had poor vision despite prior anti-VEGF treatment. Read the full announcement: ir.unitybiotechnology.com/news-releases/…

Data from our Ph 2b ASPIRE Study found that UBX1325 generally outperformed aflibercept in patients who had moderate DME disease severity, potentially addressing a treatment breakthrough for patients who have exhausted existing therapies. Read more: bit.ly/3RjoS5R

Our collaboration with Vestrum Health, CorEvitas, LLC has been instrumental in driving efficiency and accelerating patient enrollment in our ASPIRE Phase 2b #DME study. Hear from Sara Huang, SVP of Clinical Operations on the impact of this partnership below.

Today we reported Q1 2025 financial results and provided forward-looking business updates as we anticipate full 36-week Phase 2b ASPIRE data in Q2. See the earnings release: ir.unitybiotechnology.com/news-releases/…

The Phase 2 BEHOLD study data results of UBX1325 in patients with diabetic macular edema (DME) were published in the NEJM Evidence peer-reviewed journal. Read the full announcement and access the article: ir.unitybiotechnology.com/news-releases/…

We’ll be presenting first time results from the ASPIRE Phase 2b study of UBX1325 for #DME at #ARVO2025 this Wednesday, May 7. Arshad Khanani, M.D., M.A., FASRS will host the presentation onsite at 11:00 a.m. MDT. More details: ir.unitybiotechnology.com/news-releases/…

As the aging biology field evolves, we’re learning more about the role of cellular senescence in diseases. CEO Anirvan Ghosh discussed our approach as pioneers in the senolytics field and our recent Phase 2b ASPIRE trial results. Read on Longevity Technology: longevity.technology/news/weve-show…

Today we announced complete 36 week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema #DME who had poor vision despite prior anti-VEGF treatment. Read the full announcement: ir.unitybiotechnology.com/news-releases/…